Skip to main content
Premium Trial:

Request an Annual Quote

Linkage Biosciences Raises $2M in Series B Round

Premium

Linkage Biosciences said this week that it has closed a Series B financing round worth $2 million.

Linkage markets the LinkSeq HLA product line, which uses a proprietary software and chemistry platform in conjunction with real-time PCR instrumentation for HLA typing. According to the company, LinkSeq is an end-point PCR process that uses allele-specific amplification combined with SYBR Green to detect PCR products on the instrument using melt-curve analysis.

Fisher Capital and Greenhouse Capital Partners led the Series B round, which follows $2 million in Series A financing that the company raised in 2009 and $1 million in venture financing from Greenhouse Capital in 2007.

Linkage said it will use the funds to expand its manufacturing capabilities, complete regulatory requirements in the US and Europe, and accelerate the development of additional molecular tests.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more